These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 31012786)

  • 21. Could the RTS,S/AS01 meningitis safety signal really be a protective effect of rabies vaccine?
    Gessner BD; Knobel DL; Conan A; Finn A
    Vaccine; 2017 Feb; 35(5):716-721. PubMed ID: 28065475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children.
    Olotu A; Fegan G; Wambua J; Nyangweso G; Leach A; Lievens M; Kaslow DC; Njuguna P; Marsh K; Bejon P
    N Engl J Med; 2016 Jun; 374(26):2519-29. PubMed ID: 27355532
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers.
    von Seidlein L; Hanboonkunupakarn B; Jittamala P; Pongsuwan P; Chotivanich K; Tarning J; Hoglund RM; Winterberg M; Mukaka M; Peerawaranun P; Sirithiranont P; Doran Z; Ockenhouse CF; Ivinson K; Lee C; Birkett AJ; Kaslow DC; Singhasivanon P; Day NPJ; Dondorp AM; White NJ; Pukrittayakamee S
    Hum Vaccin Immunother; 2020; 16(1):33-41. PubMed ID: 31306084
    [No Abstract]   [Full Text] [Related]  

  • 24. Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial.
    White MT; Verity R; Griffin JT; Asante KP; Owusu-Agyei S; Greenwood B; Drakeley C; Gesase S; Lusingu J; Ansong D; Adjei S; Agbenyega T; Ogutu B; Otieno L; Otieno W; Agnandji ST; Lell B; Kremsner P; Hoffman I; Martinson F; Kamthunzu P; Tinto H; Valea I; Sorgho H; Oneko M; Otieno K; Hamel MJ; Salim N; Mtoro A; Abdulla S; Aide P; Sacarlal J; Aponte JJ; Njuguna P; Marsh K; Bejon P; Riley EM; Ghani AC
    Lancet Infect Dis; 2015 Dec; 15(12):1450-8. PubMed ID: 26342424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transcriptional correlates of malaria in RTS,S/AS01-vaccinated African children: a matched case-control study.
    Moncunill G; Carnes J; Chad Young W; Carpp L; De Rosa S; Campo JJ; Nhabomba A; Mpina M; Jairoce C; Finak G; Haas P; Muriel C; Van P; Sanz H; Dutta S; Mordmüller B; Agnandji ST; Díez-Padrisa N; Williams NA; Aponte JJ; Valim C; Neafsey DE; Daubenberger C; McElrath MJ; Dobaño C; Stuart K; Gottardo R
    Elife; 2022 Jan; 11():. PubMed ID: 35060479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The RTS,S/AS01 malaria vaccine in children 5 to 17 months of age at first vaccination.
    Vandoolaeghe P; Schuerman L
    Expert Rev Vaccines; 2016 Dec; 15(12):1481-1493. PubMed ID: 27841689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial.
    Aponte JJ; Aide P; Renom M; Mandomando I; Bassat Q; Sacarlal J; Manaca MN; Lafuente S; Barbosa A; Leach A; Lievens M; Vekemans J; Sigauque B; Dubois MC; Demoitié MA; Sillman M; Savarese B; McNeil JG; Macete E; Ballou WR; Cohen J; Alonso PL
    Lancet; 2007 Nov; 370(9598):1543-51. PubMed ID: 17949807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models.
    Penny MA; Verity R; Bever CA; Sauboin C; Galactionova K; Flasche S; White MT; Wenger EA; Van de Velde N; Pemberton-Ross P; Griffin JT; Smith TA; Eckhoff PA; Muhib F; Jit M; Ghani AC
    Lancet; 2016 Jan; 387(10016):367-375. PubMed ID: 26549466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria.
    Olotu A; Moris P; Mwacharo J; Vekemans J; Kimani D; Janssens M; Kai O; Jongert E; Lievens M; Leach A; Villafana T; Savarese B; Marsh K; Cohen J; Bejon P
    PLoS One; 2011; 6(10):e25786. PubMed ID: 21998698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RTS,S/AS01 malaria vaccine pilot implementation in western Kenya: a qualitative longitudinal study to understand immunisation barriers and optimise uptake.
    Hoyt J; Okello G; Bange T; Kariuki S; Jalloh MF; Webster J; Hill J
    BMC Public Health; 2023 Nov; 23(1):2283. PubMed ID: 37980467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants.
    Abdulla S; Oberholzer R; Juma O; Kubhoja S; Machera F; Membi C; Omari S; Urassa A; Mshinda H; Jumanne A; Salim N; Shomari M; Aebi T; Schellenberg DM; Carter T; Villafana T; Demoitié MA; Dubois MC; Leach A; Lievens M; Vekemans J; Cohen J; Ballou WR; Tanner M
    N Engl J Med; 2008 Dec; 359(24):2533-44. PubMed ID: 19064623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial.
    Aide P; Aponte JJ; Renom M; Nhampossa T; Sacarlal J; Mandomando I; Bassat Q; Manaca MN; Leach A; Lievens M; Vekemans J; Dubois MC; Loucq C; Ballou WR; Cohen J; Alonso PL
    PLoS One; 2010 Nov; 5(11):e13838. PubMed ID: 21079803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The RTS,S/AS01 malaria vaccine in children aged 5-17 months at first vaccination].
    Vandoolaeghe P; Schuerman L
    Pan Afr Med J; 2018; 30():142. PubMed ID: 30374388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naïve adults.
    Leroux-Roels G; Leroux-Roels I; Clement F; Ofori-Anyinam O; Lievens M; Jongert E; Moris P; Ballou WR; Cohen J
    Hum Vaccin Immunother; 2014; 10(8):2211-9. PubMed ID: 25424924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02(D) malaria vaccine in infants living in a malaria-endemic region.
    Abdulla S; Salim N; Machera F; Kamata R; Juma O; Shomari M; Kubhoja S; Mohammed A; Mwangoka G; Aebi T; Mshinda H; Schellenberg D; Carter T; Villafana T; Dubois MC; Leach A; Lievens M; Vekemans J; Cohen J; Ballou WR; Tanner M
    Malar J; 2013 Jan; 12():11. PubMed ID: 23297680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and safety of the RTS,S/AS01 malaria vaccine co-administered with measles, rubella and yellow fever vaccines in Ghanaian children: A phase IIIb, multi-center, non-inferiority, randomized, open, controlled trial.
    Asante KP; Ansong D; Kaali S; Adjei S; Lievens M; Nana Badu L; Agyapong Darko P; Boakye Yiadom Buabeng P; Boahen O; Maria Rettig T; Agutu C; Benard Ekow Harrison S; Ntiamoah Y; Adomako Anim J; Adeniji E; Agordo Dornudo A; Gvozdenovic E; Dosoo D; Sambian D; Owusu-Boateng H; Ato Wilson E; Prempeh F; Vandoolaeghe P; Schuerman L; Owusu-Agyei S; Agbenyega T; Ofori-Anyinam O
    Vaccine; 2020 Apr; 38(18):3411-3421. PubMed ID: 32192811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. From the circumsporozoite protein to the RTS, S/AS candidate vaccine.
    Cohen J; Nussenzweig V; Nussenzweig R; Vekemans J; Leach A
    Hum Vaccin; 2010 Jan; 6(1):90-6. PubMed ID: 19806009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Case reduction and cost-effectiveness of the RTS,S/AS01 malaria vaccine alongside bed nets in Lilongwe, Malawi.
    Bell GJ; Loop M; Topazian HM; Hudgens M; Mvalo T; Juliano JJ; Kamthunzi P; Tegha G; Mofolo I; Hoffman I; Bailey JA; Emch M
    Vaccine; 2020 May; 38(25):4079-4087. PubMed ID: 32362527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential effect modification of RTS,S/AS01 malaria vaccine efficacy by household socio-economic status.
    Gyaase S; Asante KP; Adeniji E; Boahen O; Cairns M; Owusu-Agyei S
    BMC Public Health; 2021 Jan; 21(1):240. PubMed ID: 33509156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine.
    Neafsey DE; Juraska M; Bedford T; Benkeser D; Valim C; Griggs A; Lievens M; Abdulla S; Adjei S; Agbenyega T; Agnandji ST; Aide P; Anderson S; Ansong D; Aponte JJ; Asante KP; Bejon P; Birkett AJ; Bruls M; Connolly KM; D'Alessandro U; Dobaño C; Gesase S; Greenwood B; Grimsby J; Tinto H; Hamel MJ; Hoffman I; Kamthunzi P; Kariuki S; Kremsner PG; Leach A; Lell B; Lennon NJ; Lusingu J; Marsh K; Martinson F; Molel JT; Moss EL; Njuguna P; Ockenhouse CF; Ogutu BR; Otieno W; Otieno L; Otieno K; Owusu-Agyei S; Park DJ; Pellé K; Robbins D; Russ C; Ryan EM; Sacarlal J; Sogoloff B; Sorgho H; Tanner M; Theander T; Valea I; Volkman SK; Yu Q; Lapierre D; Birren BW; Gilbert PB; Wirth DF
    N Engl J Med; 2015 Nov; 373(21):2025-2037. PubMed ID: 26488565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.